Holen Sie sich die Stockscreener-App
12.89
2.71%
0.34
Handel nachbörslich:
12.89
Schlusskurs vom Vortag:
$12.55
Offen:
$12.6
24-Stunden-Volumen:
188.02K
Relative Volume:
0.84
Marktkapitalisierung:
$392.38M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-10.15
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+7.60%
1M Leistung:
+10.45%
6M Leistung:
+71.64%
1J Leistung:
+61.73%
1-Tages-Spanne:
$12.52
$13.19
1-Wochen-Bereich:
$11.19
$13.19
52-Wochen-Spanne:
$5.45
$15.11
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.89 | 392.38M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace (NPCE) Projected to Post Earnings on Wednesday - MarketBeat
JPMorgan Chase & Co. Purchases 52,829 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Nantahala Capital Management LLC Sells 45,817 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Study: NeuroPace’s Technology Can Help Reduce Epileptic Seizures - Medical Product Outsourcing
28,547 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Purchased by Walleye Capital LLC - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co. - Defense World
Retail investors who hold 34% of NeuroPace, Inc. (NASDAQ:NPCE) gained 10%, institutions profited as well - simplywall.st
Geode Capital Management LLC Has $3.62 Million Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Rises By 45.8% - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - marketscreener.com
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com Australia
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Q1 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):